ÂÜÀòÂÒÂ×

Dr. Iain D. Dukes is a Venture Partner at OrbiMed Advisors.

Dr. Dukes previously served as Senior Vice-President and Head of business development and licensing for Merck Research Laboratories. Prior to joining Merck, Dr. Dukes was Vice President of External Research and Development at Amgen. Dr. Dukes has also served as President and CEO, and a member of the Board of Directors, of Essentialis Therapeutics, a clinical-stage biotechnology company focused on the development of breakthrough medicines for the treatment of rare metabolic diseases.

Previously, Dr. Dukes was Vice-President of Scientific and Technology licensing at GlaxoSmithKline, and prior to that, he held various positions at Glaxo Wellcome, including head of exploratory development for metabolic and urogenital diseases and head of the Ion Channel Drug Discovery Group. Dr. Dukes is Chairman of Iovance Biotherapeutics (NASDAQ: IOVA) and serves on the Board of Directors of Themis Biosciences (acquired by Merck & Co), Ikena Oncology, KaNDy Therapeutics (previously as Chairman, acquired by Bayer AG), NeRRe Therapeutics, ReViral Limited, and ENYO Therapeutics. Dr. Dukes co-founded and is Chief Executive Officer of Theseus Pharmaceuticals; co-founded and serves on the Board of Directors of Kartos Therapeutics where he is President; and co-founded Telios Pharma, where he is President and serves on the Board of Directors. He is also Executive Chairman of Angiex.

Dr. Dukes holds an M.A. and D.Phil, from the University of Oxford, an MSc. in Cardiovascular Studies from the University of Leeds, and a B.Sc. in Pharmacology from the University of Bath.